Benefits Seen for Rubraca in Certain Advanced Ovarian Cancers in Phase 2 Study

Benefits Seen for Rubraca in Certain Advanced Ovarian Cancers in Phase 2 Study
Ovarian cancer patients with a BRCA mutation who responded to their last line of platinum-based chemotherapy are more likely to benefit from Rubraca (rucaparib) than those resistant or refractory to platinum treatment, according to new data from the Phase 2 ARIEL2 study. Results were recently presented at the 2017 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer in National Harbor, Maryland, in two oral plenary sessions. The first presentation, titled "Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: Integrated summary of efficacy and safety from the phase II study ARIEL2" was given by Gottfried E. Konecny, MD, associate professor of Medicine, Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles. The second abstract, "BRCA1 and RAD51C promoter hypermethylation confer sensitivity to the PARP inhibitor rucaparib in patients with relapsed, platinum-sensitive ovarian carcinoma in ARIEL2 Part 1," was presented by Elizabeth M. Swisher, MD, University of Washington Medical Center, Seattle. The ARIEL2 study (NCT01891344) is a two-part, open-label trial designed to identify which ovarian cancer patients are
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *